Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.56 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | RXRB | P28702 | 1/20 | 0.53 |
| ▸ | RXRG | P48443 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426732 | 0.89 | WDR5 (0.56) | WDR5POLBMAOBAOC3FKBP1A | |
| SCHEMBL1308577 | 0.84 | WDR5 (0.62) | WDR5POLBMAOBAOC3FKBP1A | |
| SCHEMBL29590819 | 0.84 | WDR5 (0.62) | WDR5POLBMAOBAOC3FKBP1A | |
| SCHEMBL523934 | 0.84 | LMNA (0.64) | WDR5POLBMAOBAOC3FKBP1A | |
| SCHEMBL29447016 | 0.84 | LMNA (0.64) | WDR5POLBMAOBAOC3FKBP1A | |
| SCHEMBL6849640 | 0.83 | WDR5 (0.57) | WDR5POLBRXRARXRBRXRG | |
| SCHEMBL6846925 | 0.83 | KDM4E (0.58) | WDR5POLBRXRARXRBRXRG | |
| SCHEMBL9205686 | 0.82 | WDR5 (0.65) | WDR5POLBMAOBAOC3FKBP1A | |
| SCHEMBL11280610 | 0.82 | WDR5 (0.60) | WDR5POLBMAOBAOC3FKBP1A | |
| SCHEMBL7842545 | 0.82 | WDR5 (0.70) | WDR5POLBMAOBAOC3FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224255-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-05 | — | — | EP | claimed |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-09-22 | — | — | US | claimed |
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-10-26 | — | — | US | claimed |
| CN-102516196-B | Alpha, beta-unsaturated ketone compound containing thiazole heterocycle, its preparation method and application | UNIV SHANDONG | 2014-09-03 | — | — | CN | claimed |
| EP-3224255-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-05 | — | — | EP | disclosed |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| CN-109563043-A | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-04-02 | — | — | CN | disclosed |
| EP-2875001-B1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-01-09 | — | — | EP | disclosed |
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3224255-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2017-10-04 | — | — | EP | disclosed |
| US-9434695-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-09-06 | — | — | US | disclosed |
| WO-2016083818-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
| EP-2755949-A1 | FUNGICIDAL 4-SUBSTITUTED-3-{PHENYL[(HETEROCYCLYLMETHOXY)IMINO]METHYL}-1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2014-07-23 | — | — | EP | disclosed |
| CN-103570630-A | Heterocyclic nitrogen derivative and application thereof in medicines | GUANGDONG HEC PHARMACEUTICAL | 2014-02-12 | — | — | CN | disclosed |
| WO-2014012360-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-01-23 | — | — | WO | disclosed |
| WO-2013037717-A1 | FUNGICIDAL 4-SUBSTITUTED-3-{PHENYL[(HETEROCYCLYLMETHOXY)IMINO]METHYL}-1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
| EP-0341694-B1 | Method for production of 3-exomethylenecepham derivatives | OTSUKA KAGAKU KK (JP) | 1995-09-06 | — | — | EP | disclosed |
| US-4958018-A | REACTING A 3-HALOMETHYL-3-CEPHEM WITH A LEAD REDUCING AGENT | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1990-09-18 | — | — | US | disclosed |
| EP-0341694-A2 | Method for production of 3-exomethylenecepham derivatives | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1989-11-15 | — | — | EP | disclosed |
| US-4031084-A | Process for cephalosporin antibiotic intermediates | ELI LILLY AND COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | WDR5 2586/4885POLB 3826/4885MAOB 137/4885 |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | WDR5 2586/4885POLB 3826/4885MAOB 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.